Stay updated on Nivolumab for ALK+ ALCL: Clinical Trial

Sign up to get notified when there's something new on the Nivolumab for ALK+ ALCL: Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Nivolumab for ALK+ ALCL: Clinical Trial page

  1. Check
    5 days ago
    Change Detected
    Summary
    The NIH announcement banner about updates to AI-related terminology and transition FAQs is no longer displayed.
    Difference
    1%
    Check dated 2026-11-09T14:28:44.000Z thumbnail image
  2. Check
    11 days ago
    Change Detected
    Summary
    The footer revision label changed from v3.7.2 to v3.8.0 while the study record remains unavailable behind a 403 error.
    Difference
    0.2%
    Check dated 2026-11-02T15:54:55.000Z thumbnail image
  3. Check
    19 days ago
    Change Detected
    Summary
    A notice announces NIH’s transition from “Artificial Intelligence” to “Super Intelligence” terminology. The study record itself continues to show a 403 error.
    Difference
    1%
    Check dated 2026-10-26T14:44:48.000Z thumbnail image
  4. Check
    26 days ago
    Change Detected
    Summary
    The site footer revision changes from v3.7.1 to v3.7.2 on the 403 error page.
    Difference
    0.2%
    Check dated 2026-10-19T14:35:13.000Z thumbnail image
  5. Check
    33 days ago
    Change Detected
    Summary
    The site footer revision identifier changes from v3.7.0 to v3.7.1; the page continues to display a 403 Forbidden error.
    Difference
    0.2%
    Check dated 2026-10-12T15:30:41.000Z thumbnail image
  6. Check
    53 days ago
    Change Detected
    Summary
    Access to the NCT03703050 study record is blocked by a 403 Forbidden page, replacing the previous study content. The page no longer shows the study details, locations, and related submission history, preventing users from viewing the trial information.
    Difference
    18%
    Check dated 2026-09-21T21:49:25.000Z thumbnail image

Stay in the know with updates to Nivolumab for ALK+ ALCL: Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Nivolumab for ALK+ ALCL: Clinical Trial page.